Skip to main content
Top
Published in: Obesity Surgery 1/2012

01-01-2012 | Clinical Research

Prevalence of Endocrine Disorders in Morbidly Obese Patients and the Effects of Bariatric Surgery on Endocrine and Metabolic Parameters

Authors: Draženka Janković, Peter Wolf, Christian-Heinz Anderwald, Yvonne Winhofer, Miriam Promintzer-Schifferl, Astrid Hofer, Felix Langer, Gerhard Prager, Bernhard Ludvik, Alois Gessl, Anton Luger, Michael Krebs

Published in: Obesity Surgery | Issue 1/2012

Login to get access

Abstract

Background

Several endocrine abnormalities, including hypothyroidism and Cushing’s syndrome (CS), are considered as causative factors of obesity. The aim of this study was to evaluate the prevalence of endocrine disorders and obesity-associated co-morbidities, as well as the impact of substantial weight loss.

Methods

Screening was performed in 433 consecutive morbidly obese patients (age 41 ± 12 years; BMI 47 ± 6.9 kg/m2; women 76%). A 1-mg dexamethasone suppression test (1-mg DST) was conducted to exclude CS, and thyrotropin (TSH) was measured to exclude hypothyroidism. Insulin sensitivity was estimated from oral glucose tolerance tests employing the Clamp-like index. Examinations were carried out at baseline, as well as at 6 and 12 months postoperatively.

Results

The prevalence of CS was below 0.6%. Before surgery, TSH was elevated compared to an age- and sex-matched normal weight control group (2.4 ± 1.2 vs. 1.5 ± 0.7 μU/ml; p < 0.001). The NCEP criteria of metabolic syndrome (MetS) were fulfilled by 39.5% of the patients. Impaired glucose tolerance and diabetes mellitus were observed in 23.5% and 22.6%, respectively. Seventy-two percent were insulin resistant. During follow-up, weight (BMI 47 ± 6.9 vs. 36 ± 6.4 vs. 32 ± 6.6 kg/m2; p < 0.001) and TSH decreased significantly (2.4 ± 1.2 vs. 1.8 ± 1.0 vs. 1.8 ± 1.0 μU/ml; p < 0.001). Serum cortisol was higher in the MetS+-group compared to the MetS--group (15.0 ± 6.3 vs. 13.5 ± 6.3 μg/dl; p = 0.003).

Conclusions

CS appears to be a rare cause of morbid obesity. Normalization of slightly elevated thyrotropin after weight loss suggests that obesity causes TSH elevation rather than the reverse.
Literature
1.
go back to reference Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am. 2003;32:895–914.PubMedCrossRef Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am. 2003;32:895–914.PubMedCrossRef
2.
go back to reference Maddox GL, Liederman V. Overweight as a social disability with medical implications. J Med Educ. 1969;44:214–20.PubMed Maddox GL, Liederman V. Overweight as a social disability with medical implications. J Med Educ. 1969;44:214–20.PubMed
3.
go back to reference Price JH, Desmond SM, Krol RA, et al. Family practice physicians’ beliefs, attitudes, and practices regarding obesity. Am J Prev Med. 1987;3:339–45.PubMed Price JH, Desmond SM, Krol RA, et al. Family practice physicians’ beliefs, attitudes, and practices regarding obesity. Am J Prev Med. 1987;3:339–45.PubMed
4.
go back to reference Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16:73–8.PubMedCrossRef Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16:73–8.PubMedCrossRef
5.
go back to reference Sari R, Balci MK, Altunbas H, et al. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf). 2003;59:258–62.CrossRef Sari R, Balci MK, Altunbas H, et al. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf). 2003;59:258–62.CrossRef
6.
go back to reference Raftopoulos Y, Gagne DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509–13.PubMedCrossRef Raftopoulos Y, Gagne DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509–13.PubMedCrossRef
7.
go back to reference Fazylov R, Soto E, Cohen S, et al. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644–7.PubMedCrossRef Fazylov R, Soto E, Cohen S, et al. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644–7.PubMedCrossRef
8.
go back to reference Alagna S, Cossu ML, Masala A, et al. Evaluation of serum leptin levels and thyroid function in morbidly obese patients treated with bariatric surgery. Eat Weight Disord. 2003;8:95–9.PubMed Alagna S, Cossu ML, Masala A, et al. Evaluation of serum leptin levels and thyroid function in morbidly obese patients treated with bariatric surgery. Eat Weight Disord. 2003;8:95–9.PubMed
9.
go back to reference Buscemi S, Verga S, Maneri R, et al. Influences of obesity and weight loss on thyroid hormones. A 3–3.5-year follow-up study on obese subjects with surgical bilio-pancreatic by-pass. J Endocrinol Invest. 1997;20:276–81.PubMed Buscemi S, Verga S, Maneri R, et al. Influences of obesity and weight loss on thyroid hormones. A 3–3.5-year follow-up study on obese subjects with surgical bilio-pancreatic by-pass. J Endocrinol Invest. 1997;20:276–81.PubMed
10.
go back to reference Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88:5808–13.PubMedCrossRef Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88:5808–13.PubMedCrossRef
11.
go back to reference Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193–202.PubMedCrossRef Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193–202.PubMedCrossRef
12.
go back to reference Anderson Jr GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609–15.PubMedCrossRef Anderson Jr GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609–15.PubMedCrossRef
13.
go back to reference Tiryakioglu O, Ugurlu S, Yalin S, et al. Screening for Cushing’s syndrome in obese patients. Clinics (Sao Paulo). 2010;65:9–13.CrossRef Tiryakioglu O, Ugurlu S, Yalin S, et al. Screening for Cushing’s syndrome in obese patients. Clinics (Sao Paulo). 2010;65:9–13.CrossRef
14.
go back to reference Anderwald C, Anderwald-Stadler M, Promintzer M, et al. The Clamp-like index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care. 2007;30:2374–80.PubMedCrossRef Anderwald C, Anderwald-Stadler M, Promintzer M, et al. The Clamp-like index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care. 2007;30:2374–80.PubMedCrossRef
15.
go back to reference Promintzer M, Krebs M, Todoric J, et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007;92:4306–12.PubMedCrossRef Promintzer M, Krebs M, Todoric J, et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007;92:4306–12.PubMedCrossRef
16.
go back to reference Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011. Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011.
17.
go back to reference Nickelsen T, Lissner W, Schoffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol. 1989;94:275–80.PubMedCrossRef Nickelsen T, Lissner W, Schoffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol. 1989;94:275–80.PubMedCrossRef
18.
go back to reference Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66:632–5.CrossRef Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66:632–5.CrossRef
19.
go back to reference Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526–40.PubMedCrossRef Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526–40.PubMedCrossRef
20.
go back to reference Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
21.
go back to reference Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.PubMedCrossRef Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.PubMedCrossRef
22.
23.
go back to reference Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.PubMedCrossRef Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.PubMedCrossRef
24.
go back to reference al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997;82:1118–25.PubMedCrossRef al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997;82:1118–25.PubMedCrossRef
25.
26.
go back to reference Valyasevi RW, Harteneck DA, Dutton CM, et al. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352–8.PubMedCrossRef Valyasevi RW, Harteneck DA, Dutton CM, et al. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352–8.PubMedCrossRef
27.
go back to reference Guo F, Bakal K, Minokoshi Y, et al. Leptin signaling targets the thyrotropin-releasing hormone gene promoter in vivo. Endocrinology. 2004;145:2221–7.PubMedCrossRef Guo F, Bakal K, Minokoshi Y, et al. Leptin signaling targets the thyrotropin-releasing hormone gene promoter in vivo. Endocrinology. 2004;145:2221–7.PubMedCrossRef
28.
go back to reference Kok P, Roelfsema F, Langendonk JG, et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab. 2005;90:4659–63.PubMedCrossRef Kok P, Roelfsema F, Langendonk JG, et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab. 2005;90:4659–63.PubMedCrossRef
29.
go back to reference de Moraes CM Moulin, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15:1287–91.CrossRef de Moraes CM Moulin, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15:1287–91.CrossRef
31.
go back to reference Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone– > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022–7.PubMedCrossRef Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone– > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022–7.PubMedCrossRef
32.
go back to reference Hautanen A, Raikkonen K, Adlercreutz H. Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med. 1997;241:451–61.PubMedCrossRef Hautanen A, Raikkonen K, Adlercreutz H. Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med. 1997;241:451–61.PubMedCrossRef
33.
go back to reference Manco M, Fernandez-Real JM, Valera-Mora ME, et al. Massive weight loss decreases corticosteroid-binding globulin levels and increases free cortisol in healthy obese patients: an adaptive phenomenon? Diabetes Care. 2007;30:1494–500.PubMedCrossRef Manco M, Fernandez-Real JM, Valera-Mora ME, et al. Massive weight loss decreases corticosteroid-binding globulin levels and increases free cortisol in healthy obese patients: an adaptive phenomenon? Diabetes Care. 2007;30:1494–500.PubMedCrossRef
34.
go back to reference Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99:414–23.PubMedCrossRef Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99:414–23.PubMedCrossRef
35.
go back to reference Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome. Eur J Endocrinol. 2006;155:435–41.PubMedCrossRef Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome. Eur J Endocrinol. 2006;155:435–41.PubMedCrossRef
36.
go back to reference Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef
37.
go back to reference Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.PubMedCrossRef Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.PubMedCrossRef
38.
go back to reference Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.PubMedCrossRef Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.PubMedCrossRef
39.
go back to reference Munoz R, Carvajal C, Escalona A, et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg. 2009;19:764–70.PubMedCrossRef Munoz R, Carvajal C, Escalona A, et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg. 2009;19:764–70.PubMedCrossRef
40.
go back to reference Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692–701.PubMedCrossRef Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692–701.PubMedCrossRef
41.
go back to reference Ward AM, Fall CH, Stein CE, et al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf). 2003;58:500–5.CrossRef Ward AM, Fall CH, Stein CE, et al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf). 2003;58:500–5.CrossRef
42.
go back to reference Ravaja N, Keltikangas-Jarvinen L, Viikari J. Life changes, locus of control and metabolic syndrome precursors in adolescents and young adults: a three-year follow-up. Soc Sci Med. 1996;43:51–61.PubMedCrossRef Ravaja N, Keltikangas-Jarvinen L, Viikari J. Life changes, locus of control and metabolic syndrome precursors in adolescents and young adults: a three-year follow-up. Soc Sci Med. 1996;43:51–61.PubMedCrossRef
43.
go back to reference Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30:569–72.PubMedCrossRef Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30:569–72.PubMedCrossRef
44.
go back to reference Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50.PubMedCrossRef Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50.PubMedCrossRef
45.
go back to reference Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2010. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2010.
46.
go back to reference Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–9.PubMedCrossRef Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–9.PubMedCrossRef
47.
go back to reference Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100:1166–73.PubMedCrossRef Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100:1166–73.PubMedCrossRef
48.
go back to reference Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMedCrossRef Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMedCrossRef
Metadata
Title
Prevalence of Endocrine Disorders in Morbidly Obese Patients and the Effects of Bariatric Surgery on Endocrine and Metabolic Parameters
Authors
Draženka Janković
Peter Wolf
Christian-Heinz Anderwald
Yvonne Winhofer
Miriam Promintzer-Schifferl
Astrid Hofer
Felix Langer
Gerhard Prager
Bernhard Ludvik
Alois Gessl
Anton Luger
Michael Krebs
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 1/2012
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0545-4

Other articles of this Issue 1/2012

Obesity Surgery 1/2012 Go to the issue